These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
954 related articles for article (PubMed ID: 25420692)
1. Distinctive mucositis and feeding-tube dependency in cetuximab plus radiotherapy for head and neck cancer. Yokota T; Onoe T; Ogawa H; Hamauchi S; Iida Y; Kamijo T; Suda T; Yurikusa T; Nishimura T; Yasui H; Onitsuka T Jpn J Clin Oncol; 2015 Feb; 45(2):183-8. PubMed ID: 25420692 [TBL] [Abstract][Full Text] [Related]
2. Impact of prophylactic percutaneous endoscopic gastrostomy tube placement on treatment tolerance in head and neck cancer patients treated with cetuximab plus radiation. Yamazaki T; Enokida T; Wakasugi T; Zenda S; Motegi A; Arahira S; Akimoto T; Tahara M Jpn J Clin Oncol; 2016 Sep; 46(9):825-31. PubMed ID: 27317736 [TBL] [Abstract][Full Text] [Related]
3. Safety and efficacy of concurrent carboplatin plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin. Hamauchi S; Yokota T; Onozawa Y; Ogawa H; Onoe T; Kamijo T; Iida Y; Nishimura T; Onitsuka T; Yasui H Jpn J Clin Oncol; 2015 Dec; 45(12):1116-21. PubMed ID: 26423341 [TBL] [Abstract][Full Text] [Related]
4. Radiotherapy combined with cetuximab for locally advanced head and neck cancer: results and toxicity. Acevedo-Henao CM; Valette G; Miglierini P; Lefur E; Pradier O Cancer Radiother; 2012 Oct; 16(7):601-3. PubMed ID: 23089070 [TBL] [Abstract][Full Text] [Related]
5. Association of human papillomavirus and p16 status with mucositis and dysphagia for head and neck cancer patients treated with radiotherapy with or without cetuximab: Assessment from a phase 3 registration trial. Bonner JA; Giralt J; Harari PM; Baselga J; Spencer S; Bell D; Raben D; Liu J; Schulten J; Ang KK; Rosenthal DI Eur J Cancer; 2016 Sep; 64():1-11. PubMed ID: 27323346 [TBL] [Abstract][Full Text] [Related]
6. IMRT with simultaneous integrated boost and concurrent chemotherapy for locoregionally advanced squamous cell carcinoma of the head and neck. Montejo ME; Shrieve DC; Bentz BG; Hunt JP; Buchman LO; Agarwal N; Hitchcock YJ Int J Radiat Oncol Biol Phys; 2011 Dec; 81(5):e845-52. PubMed ID: 21167654 [TBL] [Abstract][Full Text] [Related]
7. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Bonner JA; Harari PM; Giralt J; Cohen RB; Jones CU; Sur RK; Raben D; Baselga J; Spencer SA; Zhu J; Youssoufian H; Rowinsky EK; Ang KK Lancet Oncol; 2010 Jan; 11(1):21-8. PubMed ID: 19897418 [TBL] [Abstract][Full Text] [Related]
8. Phase I study of weekly nab-paclitaxel + weekly cetuximab + intensity-modulated radiation therapy (IMRT) in patients with stage III-IVB head and neck squamous cell carcinoma (HNSCC). Fury MG; Sherman EJ; Rao SS; Wolden S; Smith-Marrone S; Mueller B; Ng KK; Dutta PR; Gelblum DY; Lee JL; Shen R; Kurz S; Katabi N; Haque S; Lee NY; Pfister DG Ann Oncol; 2014 Mar; 25(3):689-694. PubMed ID: 24496920 [TBL] [Abstract][Full Text] [Related]
9. Role of concomitant chemoradiation in locally advanced head and neck cancers. Lasrado S; Moras K; Pinto GJ; Bhat M; Hegde S; Sathian B; Luis NA Asian Pac J Cancer Prev; 2014; 15(10):4147-52. PubMed ID: 24935361 [TBL] [Abstract][Full Text] [Related]
10. Randomized phase 2 study of concomitant chemoradiotherapy using weekly carboplatin/paclitaxel with or without daily subcutaneous amifostine in patients with locally advanced head and neck cancer. Haddad R; Sonis S; Posner M; Wirth L; Costello R; Braschayko P; Allen A; Mahadevan A; Flynn J; Burke E; Li Y; Tishler RB Cancer; 2009 Oct; 115(19):4514-23. PubMed ID: 19634161 [TBL] [Abstract][Full Text] [Related]
11. Phase II study of cetuximab in combination with cisplatin and radiation in unresectable, locally advanced head and neck squamous cell carcinoma: Eastern cooperative oncology group trial E3303. Egloff AM; Lee JW; Langer CJ; Quon H; Vaezi A; Grandis JR; Seethala RR; Wang L; Shin DM; Argiris A; Yang D; Mehra R; Ridge JA; Patel UA; Burtness BA; Forastiere AA Clin Cancer Res; 2014 Oct; 20(19):5041-51. PubMed ID: 25107914 [TBL] [Abstract][Full Text] [Related]
12. Radiotherapy compliance is maintained with hypofractionation and concurrent cetuximab in locally advanced head and neck cancer. Chan A; Teoh D; Sanghera P; Hartley A Radiother Oncol; 2009 Dec; 93(3):654. PubMed ID: 19524312 [No Abstract] [Full Text] [Related]
13. Phase II study of cetuximab plus concomitant boost radiotherapy in Japanese patients with locally advanced squamous cell carcinoma of the head and neck. Okano S; Yoshino T; Fujii M; Onozawa Y; Kodaira T; Fujii H; Akimoto T; Ishikura S; Oguchi M; Zenda S; de Blas B; Tahara M; Beier F Jpn J Clin Oncol; 2013 May; 43(5):476-82. PubMed ID: 23479383 [TBL] [Abstract][Full Text] [Related]
14. Postoperative chemoradiotherapy and cetuximab for high-risk squamous cell carcinoma of the head and neck: Radiation Therapy Oncology Group RTOG-0234. Harari PM; Harris J; Kies MS; Myers JN; Jordan RC; Gillison ML; Foote RL; Machtay M; Rotman M; Khuntia D; Straube W; Zhang Q; Ang K J Clin Oncol; 2014 Aug; 32(23):2486-95. PubMed ID: 25002723 [TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of concurrent carboplatin or cetuximab plus radiotherapy for locally advanced head and neck cancer patients ineligible for treatment with cisplatin. Hamauchi S; Yokota T; Mizumachi T; Onozawa Y; Ogawa H; Onoe T; Kamijo T; Iida Y; Nishimura T; Onitsuka T; Yasui H; Homma A Int J Clin Oncol; 2019 May; 24(5):468-475. PubMed ID: 30656463 [TBL] [Abstract][Full Text] [Related]
16. Comparison of acute toxicities associated with cetuximab-based bioradiotherapy and platinum-based chemoradiotherapy for head and neck squamous cell carcinomas: A single-institution retrospective study in Japan. Sakashita T; Homma A; Hatakeyama H; Furusawa J; Kano S; Mizumachi T; Iizuka S; Onimaru R; Tsuchiya K; Yasuda K; Shirato H; Fukuda S Acta Otolaryngol; 2015 Aug; 135(8):853-8. PubMed ID: 25814008 [TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant docetaxel, cisplatin, 5-fluorouracil before concurrent chemoradiotherapy in locally advanced squamous cell carcinoma of the head and neck versus concomitant chemoradiotherapy: a phase II feasibility study. Ghi MG; Paccagnella A; D'Amanzo P; Mione CA; Fasan S; Paro S; Mastromauro C; Carnuccio R; Turcato G; Gatti C; Pallini A; Nascimben O; Biason R; Oniga F; Medici M; Rossi F; Fila G Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):481-7. PubMed ID: 15145166 [TBL] [Abstract][Full Text] [Related]
18. Cetuximab, paclitaxel, carboplatin, and radiation for head and neck cancer: a toxicity analysis. Birnbaum A; Dipetrillo T; Rathore R; Anderson E; Wanebo H; Puthwala Y; Joyce D; Safran H; Henderson D; Kennedy T; Ready N; Sio TT Am J Clin Oncol; 2010 Apr; 33(2):144-7. PubMed ID: 19786848 [TBL] [Abstract][Full Text] [Related]
19. Evaluating the role of prophylactic gastrostomy tube placement prior to definitive chemoradiotherapy for head and neck cancer. Chen AM; Li BQ; Lau DH; Farwell DG; Luu Q; Stuart K; Newman K; Purdy JA; Vijayakumar S Int J Radiat Oncol Biol Phys; 2010 Nov; 78(4):1026-32. PubMed ID: 20231073 [TBL] [Abstract][Full Text] [Related]
20. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. Bonner JA; Harari PM; Giralt J; Azarnia N; Shin DM; Cohen RB; Jones CU; Sur R; Raben D; Jassem J; Ove R; Kies MS; Baselga J; Youssoufian H; Amellal N; Rowinsky EK; Ang KK N Engl J Med; 2006 Feb; 354(6):567-78. PubMed ID: 16467544 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]